Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy, immunotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have >= grade  adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) before entering the study or those who have not recovered from AEs to ? Grade  (except for peripheral neuropathy; see Exclusion Criterion ) due to agents administered more than  weeks earlier.
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) or targeted therapies within  weeks prior to entering the study or those who have not recovered (=< grade ) from adverse events due to agents administered with the exception of any grade of alopecia
Participants who have had any of the following:\r\n* Chemotherapy in the previous  weeks ( weeks for nitrosoureas or mitomycin C)\r\n* Radiotherapy within  weeks\r\n* Investigational agents within  weeks prior to entering the study\r\n* Patients who have not recovered from significant (in the opinion of the investigator) adverse events due to previous agents administered
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Subjects who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study (e.g. start of study treatment), or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C), small molecule targeted therapy (i.e.  kinase inhibitors) within  weeks or the last dose of antibody therapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Subject who has had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Chemotherapy or radiotherapy within  week ( weeks for nitroureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Those who have had chemotherapy or radiotherapy or targeted agents within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy within  weeks or five half-lives, whichever is shorter, ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapy
Prior chemotherapy or radiation within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Exposure to chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Use of any other chemotherapy, radiotherapy, or experimental drug or therapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to enrollment on study or those who have not recovered from adverse events >= grade  due to agents administered more than  weeks earlier except for stable grade  neuropathy
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; corticosteroid treatment is allowed
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy/radiotherapy and/or targeted agents within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; the washout chemotherapy/radiotherapy and/or target agents for these patients will be at the investigators discretion.
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had radiotherapy or chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosourea or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C,  half-lives for targeted therapies) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; concurrent palliative radiotherapy is allowed at the discretion of the treating physician
Subjects who have had immunotherapy, chemotherapy, or radiation therapy within  days ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients who have had targeted therapy will be required to wait  weeks due to short half-life of the drugs; treatment with bisphosphonates is permitted
Prior chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) or radiotherapy within  weeks for antecedent malignancies prior to entering the study, or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier (e.g. alopecia, hypothyroid, neuropathy, etc.)
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C, or monoclonal antibodies such as bevacizumab, cetuximab or panitumumab) prior to entering the study or those who have not recovered to =< grade  adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade  adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had treatment with chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier are excluded; this does not include the use of steroids which may continue until two days prior to enrollment
Participants who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry or those with adverse events due to agents administered more than  weeks earlier that have not resolved to =< grade  per Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; participants who have been treated with a tyrosine kinase inhibitor within  days
Previously treated with irinotecan, or had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study, or not recovered from adverse effects due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to study enrollment or those who have not recovered from adverse events due to agents administered more than  weeks prior to study enrollment
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients may have received dexamethasone within  weeks prior to entering study
Participants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; in addition, no small molecule kinase inhibitors or any other type of investigational agent may have been administered within  weeks before first dose of study treatment
Chemotherapy, radiotherapy or hormonal therapy within  weeks ( weeks for nitrosoureas, mitomycin C or bevacizumab), or who have not recovered from the adverse events to < grade  due to previous agents administered more than  weeks prior to study day 
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  days ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients who have had prior treatment with any PARP inhibitors are ineligible
Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), immunosuppressive therapy, or steroids within  weeks ( weeks for nitrosoureas or mitomycin C) before entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier (with the exception of alopecia and neuropathy); no radiation is allowed on study
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Prior systemic chemotherapy for anaplastic thyroid cancer\r\n* Patients who have had chemotherapy or radiotherapy within  weeks of registration ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered >  weeks previously\r\n* Patients receiving other investigational agents
Patient who has had chemotherapy, radiotherapy, or biological therapy, within  days ( days for nitrosoureas or mitomycin C) or who has not recovered from adverse events due to agents administered more than  days earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events to =< grade  due to agents administered more than  weeks earlier; for investigational targeted therapies patients will need to clear for  half lives (not applicable to standard of care therapies)
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C,  weeks for rituximab) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Receipt of chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Chemotherapy, within  weeks prior to entering the study ( weeks for nitrosoureas or mitomycin) or those who have not recovered to less than or equal to grade  from adverse events due to agents administered more than  weeks earlier
Participants may not have had chemotherapy or radiation therapy (RT) within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered to =< grade  from adverse events due to agents administered more than  weeks earlier; patients should not have received hormonal therapy for treatment of their cancer within  weeks of study entry
Patients who have had targeted therapy, chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade =<  or baseline) from clinically significant adverse events due to agents administered more than  weeks earlier (alopecia and fatigue excluded); clinical significance to be determined by investigator
Participants who have had any prior systemic therapy for CLL, or chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) for some other indication prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) or radiation therapy within  weeks prior to entering the study or those who have not recovered to =< grade  (except alopecia) from adverse events (as per the revised NCI CTCAE version ) due to agents administered more than  weeks earlier
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patient has had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas, anti-angiogenic agents, or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had anti-VEGFR tyrosine kinase inhibitor within  week, mTOR inhibitor within  week or anti-VEGF antibody therapy within  weeks prior to entering the study; patients who have had other forms of chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to day  or those who have not recovered from adverse events (AEs) due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Use of any other chemotherapy, radiotherapy, or experimental drug or therapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to enrollment on study or those who have not recovered from adverse events =< grade  due to agents administered more than  weeks earlier except for stable grade  neuropathy
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; current treatment with leuprolide or other gonadotropin-releasing hormone (GnRH) agonists is permitted on the Phase I portion of the study
EXPANSION COHORT ONLY: Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy =<  weeks ( weeks for nitrosoureas or mitomycin C) prior to registration or those who have not recovered from adverse events due to agents administered >=  weeks earlier; patients may not be receiving any other investigational agents
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for radiotherapy to the lung fields and  weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade  (or =< tolerable grade  for neuropathy) adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier to grade  or below (unless approved by the study chair)
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Subject who has had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from prior treatment related toxicity with persistent symptoms >/= grade  due to agents administered more than  weeks earlier.
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C), or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > ) due to agents administered more than  weeks earlier.
Patients who have had chemotherapy or radiotherapy within  days ( weeks for nitrosoureas or mitomycin C) prior to study screening or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy (non-tyrosine kinase inhibitor [TKI]) or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Chemotherapy, radiotherapy, or surgery within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (toxicities not improved to =< grade ) due to agents administered more than  weeks earlier; additionally, patients experiencing disease progression within  months of platinum-based therapy will be excluded from trial participation
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy or targeted agents within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier will be excluded
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
